The MercyOne Northeast Family Medicine and Residency Program is seeking participants for a clinical study of a drug aimed at slowing Alzheimer’s, according to the Waterloo Cedar Falls Courier. The Waterloo location is one of 300 throughout the world that will be studying the effectiveness of Donanemab in the slowing of the disease. It will be a randomized, double blind, placebo controlled study, meaning there is an equal chance participants will get the placebo or the active drug. The doctors will not know which participants get the drug. To participate patients must be between 60 and 85 and be diagnosed with early, symptomatic Alzheimer’s disease that has worsened in the last six months. The program is expected to hit its cap in the next two or three weeks.
